Recently, Merit Medical announced that it has agreed to acquire Cook Medical’s lead management business for $210 million (approximately RMB 1.5 billion). Merit expects to provide funding for the transaction through a combination of cash on hand and borrowing under its long-term credit line. The proposed transaction is expected to be completed in the fourth quarter of 2024, subject to obtaining or waiving (in accordance with the provisions of the asset purchase agreement) approval for certain closing conditions, including antitrust laws and other customary closing conditions. It is understood that Cook Medical’s lead management business has a 34 year operating history, providing a comprehensive end-to-end medical device and accessory product portfolio for patients who need to remove or replace pacemaker or implantable cardioverter defibrillator (ICD) leads for lead management procedures. 01. Breaking through industry difficulties Cook Medical’s lead management business provides medical equipment and accessories for potential customer management programs. ...
Recently, the Equipment Review Center of the National Medical Products Administration released the results of the special review application for innovative medical devices (No. 8 of 2024), intending to approve 5 innovative medical device projects to enter the special review process. 1. Human homologous recombination repair defect detection kit (high-throughput sequencing method): Xiamen Aide Biomedical Technology Co., Ltd Xiamen Aide Biopharmaceutical Technology Co., Ltd. (hereinafter referred to as Aide Biotechnology) was established in 2008. It has long been deeply involved in the field of tumor gene testing, focusing on tumor drug co diagnosis. Relying on powerful bioinformatics algorithms, it has laid out detection reagents, software, and supporting instruments for various technology platforms, and provides detection services and drug clinical research services. In terms of products, Eide Biological Products has a wide range of products, which can detect the mutations of EGFR, KRAS, BRAF and other common genes, covering the disease ...
The following article is from the biological world, authored by the author Transforming growth factor beta (TGF – β) is a multifunctional cytokine that plays a critical role in processes such as development, immunity, cancer, and fibrosis. TGF – β has three different gene expression products (TGF – β 1, TGF – β 2, and TGF – β 3), all of which are expressed in an inactive (latent) form, namely L-TGF – β, and “activation” is crucial for its function. Most therapeutic strategies targeting TGF – β do not target specific latent and/or activation mechanisms, but rather inhibit the overall TGF – β signaling pathway and exhibit significant toxicity. A deeper understanding of latency and activation may contribute to the development of better TGF – β targeted therapeutic strategies. Traditionally, it is believed that mature TGF – β must physically dissociate from L-TGF – β 1 before signal transduction can ...
picture Writing | Sister Xian Extracellular vesicles are important mediators of intercellular communication, consisting of small vesicles with diameters ranging from 30-150 nanometers. They can transport biomolecules such as proteins, lipids, and nucleic acids from one cell to another, thereby regulating the behavior of recipient cells. Due to their roles in various physiological and pathological processes, extracellular vesicles have become a hot topic in biomedical research. Studies have found that as age increases, the number and composition of circulating extracellular vesicles change, which may have significant impacts on the aging process. The changes in miRNA and other molecules in extracellular vesicles with age may affect cell function and tissue regeneration ability [1]. However, how extracellular vesicles change during aging and the molecular mechanisms behind these changes are currently not fully understood. The formation of extracellular vesicles is a complex multi-step process involving the endosomal pathway and the biological formation of ...
In the first half of 2024, Novo Nordisk achieved revenue of 133.4 billion Danish kroner, a year-on-year increase of 24%, and its performance continued to grow. The increase in the volume of semaglutide is a key factor in the growth of performance. Ozempic, a semaglutide hypoglycemic injection, achieved revenue of 56.7 billion Danish kroner, Rybelsus, a semaglutide hypoglycemic oral agent, achieved revenue of 10.9 billion Danish kroner, and Wegovy, a semaglutide weight loss injection, achieved revenue of 21 billion Danish kroner. The total sales of semaglutide were 88.7 billion Danish kroner, a year-on-year increase of 43%, accounting for 2/3 of Novo Nordisk’s total revenue. While semaglutide is selling well around the world, Novo Nordisk is also constantly adjusting and optimizing its R&D strategy and business layout. By enriching its product portfolio, it will further strengthen its dominant position in the field of blood sugar and fat reduction. At the same ...
A price war has erupted for pneumonia vaccines, with pharmaceutical companies attempting to exchange lower prices for market share. Recently, public resource trading center websites in several provinces, including Jilin and Jiangsu, have shown that Zhifei Biological’s wholly-owned subsidiary, Zhifei Lvzhu, has reduced the price of its 0.5ml, 23-valent pneumococcal polysaccharide vaccine from 298 yuan to 209 yuan, a decrease of nearly 30%. This follows a series of price cuts for other vaccines, such as the HPV and flu vaccines, marking yet another manufacturer proactively lowering vaccine supply prices. Will other manufacturers follow suit? Watson Bio recently disclosed in a research announcement that the price of its 23-valent pneumonia vaccine has remained stable since its market introduction. Currently, the nationwide average winning bid price is lower than the adjusted prices of its competitors, and the company hopes to maintain price stability for its related products. Zhifei Biological’s 23-valent pneumococcal polysaccharide ...
On September 12, a research team from the Chinese Academy of Sciences published a result in the journal Cell, titled “Metformin decelerates aging clock in male monkeys.” After eight years of in-depth research, its findings were confirmed in primates. Metformin can significantly delay aging, especially protecting the brain cognitive function of elderly animals. This study found that the protective effect of metformin on primate aging does not depend on its traditional blood sugar and metabolic regulatory functions, but will reset the intrinsic program of cellular aging, thereby delaying cellular aging. Previously, in a research report titled “Metformin facilitates viral reservoir reactivation and their recognition by anti-HIV-1 envelope antibodies” published in the international magazine iScience, scientists from the University of Montreal and other institutions found through research that metformin may help HIV-infected people who are receiving treatment clear the reservoir of the virus in their bodies and eventually eliminate the virus. ...
Looking around the world, biotech is a group with extremely high “metabolism”. According to statistics from GF Securities, since 1990, more than 600 biotech companies have IPOed on Nasdaq. However, as of June 30, 2020, only 12 biotechs have relatively stable income and positive cash flow. Extending the timeline, from the rise of the concept of biotech in the 1980s to the present, in 40 years, there are only a few who have entered the pharma camp by buying on their own. Why is it difficult for biotech to survive for a long time? This is determined by the business model. Compared with large pharmaceutical companies with average growth but strong certainty, biotech is a divergent innovation model, and the growth process is full of uncertainty. In other words, due to the high risk of R&D and the uncertainty of sales, most biotechs can’t run the business model at all, ...
Recently, according to The Irish Times, global medical device giant Gardiner has convened a meeting with all employees of its Tullamore factory in Ireland to announce its decision to close the Tullamore factory and cease production of a product. With the closure of the factory, 315 job positions will be cut, and up to 300 employees will face layoffs. According to public information, the Tullamore factory has a total of 315 employees. The first batch of employees will resign in March and April 2025, and the second batch of employees will resign in April and May 2026. Purchased for 43.4 billion yuan, net profit increased fivefold, still facing closure The Tullamore factory was established in 1982 and has undergone several rotations over the decades. Originally established by American disposable medical product manufacturer Sherwood Medical, the Tullamore factory was acquired by Tyco Healthcare in 1998, which is now the predecessor of ...
According to the Qichacha APP, Tianjin Jiuyin Electronic Technology Co., Ltd. was recently established, with Li Kang as the legal representative and a registered capital of 500000 yuan. Its business scope includes: sales of satellite mobile communication terminals; Sales of navigation terminals; Sales of wearable smart devices; Sales of intelligent unmanned aerial vehicles, etc. Qichacha’s equity penetration shows that the company is wholly owned by Andon Health. In the field of medical applications, the “low altitude+medical rescue” unmanned aerial vehicle comprehensive solution has achieved normalized low altitude medical transportation services in multiple provinces and cities across the country. With the help of unmanned aerial vehicle technology, it innovates three key medical logistics scenarios: blood transportation, medical material distribution, and rapid response to emergency supplies. Will Jiu’an be involved in this direction in the future? Worth paying attention to. Has launched multiple wearable products, with asset management becoming one of its ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.